Literature DB >> 15636017

Overview on tools and methods to assess neuropathic trigeminal pain.

Peter Svensson1, Lene Baad-Hansen, Torben Thygesen, Gitte I Juhl, Troels Staehelin Jensen.   

Abstract

This article provides a brief overview of the tools and methods that may be useful to assess neuropathic trigeminal pain. Pain is a complex multidimensional and biopsychosocial experience. While the assessment of neuropathic trigeminal pain is complex, there are several meaningful ways available for the systematic assessment of neuropathic pain and its effects and manifestations. The key to such an analysis is a standardized pain history and examination and a good knowledge of pain mechanisms. Patients can be asked to provide detailed information about their spontaneous pain (ie, stimulus-independent pain), eg, quality, intensity, localization, time course, and modifying factors. Stimulus-dependent pain components can be characterized with clinical examination procedures and quantitative psychophysical techniques such as application of mechanical, thermal, chemical, and electrical stimuli. The description of the stimulus-dependent pain is important to reveal the function of the somatosensory system and to map the extent of hyperalgesia, hyperesthesia and allodynia, because the normal relationship between stimulus intensity and perceived intensity is distorted in many neuropathic pain conditions. In addition to the psychophysical techniques, a number of laboratory tests for assessment of trigeminal pain have been developed and tested, although critical information on sensitivity, specificity, and predictive values is still scarce. There is also a need for common guidelines on classification, diagnostic procedures, and management. This will require concerted international, interdisciplinary action.

Entities:  

Mesh:

Year:  2004        PMID: 15636017

Source DB:  PubMed          Journal:  J Orofac Pain        ISSN: 1064-6655


  8 in total

1.  Sniffing out pain: An in vivo intranasal study of analgesic efficacy.

Authors:  Sohani Maroli; H P Srinath; Chanchal Goinka; Naveen S Yadav; Archana Bhardwaj; Rana K Varghese
Journal:  J Int Oral Health       Date:  2014-02-26

Review 2.  [Suggestion for a classification of odontalgias].

Authors:  J C Türp; A Hugger; C Löst; P Nilges; H J Schindler; H J Staehle
Journal:  Schmerz       Date:  2009-10       Impact factor: 1.107

3.  Neuropathy of Trigeminal Nerve Branches After Oral and Maxillofacial Treatment.

Authors:  Jimoh Olubanwo Agbaje; Elke Van de Casteele; Marjolein Hiel; Ciska Verbaanderd; Ivo Lambrichts; Constantinus Politis
Journal:  J Maxillofac Oral Surg       Date:  2015-11-11

4.  Analysis of trigeminal nerve disorders after oral and maxillofacial intervention.

Authors:  Sareh Said Yekta; Felix Koch; Maurice B Grosjean; Marcella Esteves-Oliveira; Jamal M Stein; Alireza Ghassemi; Dieter Riediger; Friedrich Lampert; Ralf Smeets
Journal:  Head Face Med       Date:  2010-10-26       Impact factor: 2.151

Review 5.  Modulation, adaptation, and control of orofacial pathways in healthy adults.

Authors:  Meredith E Estep
Journal:  J Commun Disord       Date:  2009-04-07       Impact factor: 2.288

6.  Intraoral somatosensory abnormalities in patients with atypical odontalgia--a controlled multicenter quantitative sensory testing study.

Authors:  Lene Baad-Hansen; Maria Pigg; Susanne Eímasry Ivanovic; Hanan Faris; Thomas List; Mark Drangsholt; Peter Svensson
Journal:  Pain       Date:  2013-04-06       Impact factor: 6.961

7.  Evaluation of the anesthetic effect of epinephrine-free articaine and mepivacaine through quantitative sensory testing.

Authors:  Sareh Said Yekta-Michael; Jamal M Stein; Ernst Marioth-Wirtz
Journal:  Head Face Med       Date:  2015-02-07       Impact factor: 2.151

8.  Electric toothbrush application is a reliable and valid test for differentiating temporomandibular disorders pain patients from controls.

Authors:  Donald R Nixdorf; Azar Hemmaty; John O Look; Eric L Schiffman; Mike T John
Journal:  BMC Musculoskelet Disord       Date:  2009-07-30       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.